Skip to main content
Caplight Logo









Embleema

Embleema

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.embleema.com/

Last Round

Series A

Feb 6, 2019

Total Funding Raised

$3.82M

Company Overview

Embleema is a health technology company that provides a platform for registries and real-world studies, unifying genomic, clinical, and patient-reported data to generate regulatory-grade evidence for research organizations and life science sponsors.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Healthcare Analytics, Precision Medicine, Patient Engagement

Business Model

B2B

Customer Profile

Subscription SaaS, Data as a Service, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

real-world evidencedecentralized clinical trialsDCTreal-world dataRWDpatient registrieselectronic data captureEDCbioinformatics platformregulatory-grade evidencepatient-reported outcomesePROpatient engagement platformprecision medicineclinical trial softwareClinTechHIPAA compliance

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Embleema Comparables

Compare Embleema with similar companies based on industry and business-model similarity.

Embleema comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OM1
77%
Verana Health
76%
Dassault Systèmes
75%

Embleema Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AFeb 6, 2019
AcceleratorFeb 1, 2019

Key People

Founding team and executive leadership

Nicolas Schmidt

Chief Product Officer & Co-Founder

Founding Team

Robert Chu

Co-Founder & CEO

Founding Team

Embleema Investors

Notable investors and investment history

Embleema investors
InvestorRounds
TechstarsAccelerator, Series A
Alchemist AcceleratorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 121% MoM, reaching 801.

  • Nov 9, 2025

    Monthly visitors increased 54% MoM.

Embleema Filings

Explore SEC and related filing metadata, where available.

Embleema filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Embleema's valuation, stock price, and market status.

Is Embleema a public or private company?

Embleema is a private company.

What is the current stock price of Embleema?

Embleema is a private company with no public stock price. No recent secondary market data is available.

How much is Embleema worth (valuation)?

Valuation information for Embleema is not publicly available.

Can I buy Embleema stock?

Embleema shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Embleema's last funding round?

Embleema's most recent funding round was Series A on February 6, 2019.

Who are the main investors in Embleema?

Key investors in Embleema include Techstars.

Will Embleema IPO soon?

No public IPO plans have been announced for Embleema.

How can I track Embleema secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Embleema's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range28
Year Founded2017
Last FundingFeb 6, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?